1. Current controversies in the management of metastatic colorectal cancer
- Author
-
Encarnación González, Mª José Safont, Carmen Guillén-Ponce, Fernando Rivera, R. Vera, Manuel Valladares-Ayerbes, Carles Pericay, Javier Gallego, and Vicente Alonso
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,Colorectal cancer ,Antineoplastic Agents ,Toxicology ,chemistry.chemical_compound ,Regorafenib ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Animals ,Humans ,Combined Modality Therapy ,Panitumumab ,Pharmacology (medical) ,Molecular Targeted Therapy ,Aflibercept ,Pharmacology ,Response rate (survey) ,Evidence-Based Medicine ,Cetuximab ,business.industry ,Liver Neoplasms ,Antibodies, Monoclonal ,Prognosis ,medicine.disease ,digestive system diseases ,chemistry ,Colorectal Neoplasms ,business ,Biomarkers ,medicine.drug - Abstract
The factors affecting the decisions for the treatment for patients with metastatic colorectal cancer (mCRC) are related to the patient, the tumor, and the treatment itself. Both cetuximab and panitumumab are anti-EGFR monoclonal antibody options for patients with RAS wild-type tumors. Several trials comparing these agents with bevacizumab are analyzed in this paper. The liver is the most common site of metastases in patients with CRC, and perioperative chemotherapy has been shown to yield benefits in this setting. In the second-line treatment for mCRC, maintenance with bevacizumab after progression following first-line treatment is convenient in some groups of patients with mCRC. Also, aflibercept has demonstrated benefits in response rate, progression-free survival, and overall survival in second-line treatment, whereas regorafenib provides benefits to patients progressing on all standard therapies. Several novel therapeutic options for patients with mCRC are under development, and these are discussed.
- Published
- 2015
- Full Text
- View/download PDF